Dr. Lal Path Labs Intrinsic Value
Dr. Lal Path Labs (LALPATHLAB) median intrinsic value is ₹485.16 from 9 valuation models (range ₹323–₹809), vs current price ₹1617.20 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Dr. Lal Path Labs stock price NSE.
LALPATHLAB Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Lal Path Labs intrinsic value across 9 models vs current price ₹1617.20 — upside/downside and value range per method. Browse LALPATHLAB annual financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹485.16 | ₹388.13 - ₹582.19 | -70.0% | EPS: ₹31.44, Sector P/E: 12x |
| Book Value Method | asset | ₹323.44 | ₹291.10 - ₹355.78 | -80.0% | Book Value/Share: ₹149.29, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹485.16 | ₹436.64 - ₹533.68 | -70.0% | Revenue/Share: ₹173.10, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹646.88 | ₹582.19 - ₹711.57 | -60.0% | EBITDA: ₹844.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹646.88 | ₹517.50 - ₹776.26 | -60.0% | CF Growth: 9.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹485.16 | ₹436.64 - ₹533.68 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹485.16 | ₹436.64 - ₹533.68 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹808.60 | ₹727.74 - ₹889.46 | -50.0% | ROE: 21.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹485.16 | ₹436.64 - ₹533.68 | -70.0% | EPS: ₹31.44, BVPS: ₹149.29 |
LALPATHLAB Intrinsic Value vs Market Price — All Valuation Models
Dr. Lal Path Labs fair value range ₹323–₹809 vs current market price ₹1617.20 across 9 valuation models. Also explore LALPATHLAB stock price history to track price trends across different timeframes.
LALPATHLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Lal Path Labs median intrinsic value ₹485.16, current price ₹1617.20 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of LALPATHLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Lal Path Labs (LALPATHLAB) is ₹485.16 (median value). With the current market price of ₹1617.20, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹323.44 to ₹808.60, indicating ₹323.44 - ₹808.60.
Is LALPATHLAB undervalued or overvalued?
Based on our multi-method analysis, Dr. Lal Path Labs (LALPATHLAB) appears to be trading above calculated value by approximately 70.0%.
LALPATHLAB Financial Health — Key Ratios vs Industry Benchmarks
Dr. Lal Path Labs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.18 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
LALPATHLAB Cash Flow Quality — Operating & Free Cash Flow
Dr. Lal Path Labs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹569 Cr | ₹418 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹535 Cr | ₹523 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹456 Cr | ₹313 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹447 Cr | ₹223 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹398 Cr | ₹292 Cr | Positive Free Cash Flow | 8/10 |